| Chapter title |
Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction.
|
|---|---|
| Chapter number | 19 |
| Book title |
Chemo Fog
|
| Published in |
Advances in experimental medicine and biology, December 2009
|
| DOI | 10.1007/978-1-4419-6306-2_19 |
| Pubmed ID | |
| Book ISBNs |
978-1-4419-6305-5, 978-1-4419-6306-2
|
| Authors |
Aluise CD, Sultana R, Tangpong J, Vore M, St Clair D, Moscow JA, Butterfield DA, Christopher D. Aluise, Rukhsana Sultana, Jitbangjong Tangpong, Mary Vore, Daret St. Clair, Jeffrey A. Moscow, D. Allan Butterfield, Aluise, Christopher D., Sultana, Rukhsana, Tangpong, Jitbangjong, Vore, Mary, Clair, Daret St., Moscow, Jeffrey A., Butterfield, D. Allan |
| Abstract |
Doxorubicin (ADRIAMYCIN, RUBEX) is a chemotherapeutic agent that is commonly administered to breast cancer patients in standard chemotherapy regimens. As true of all such therapeutic cytotoxic agents, it can damage normal, noncancerous cells and might affect biochemical processes in a manner that might lead to, or contribute to, chemotherapy-induced cognitive deficits when administered either alone or in combination with other agents. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 1% |
| Pakistan | 1 | 1% |
| Unknown | 81 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 16% |
| Student > Master | 13 | 16% |
| Student > Bachelor | 10 | 12% |
| Researcher | 8 | 10% |
| Student > Doctoral Student | 7 | 8% |
| Other | 17 | 20% |
| Unknown | 15 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 18% |
| Psychology | 14 | 17% |
| Neuroscience | 12 | 14% |
| Biochemistry, Genetics and Molecular Biology | 7 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Other | 12 | 14% |
| Unknown | 19 | 23% |